At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Nov 12, 2026 at 16:54 ET
Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on revenue of $0.1M, missing the consensus EPS estimate of -$1.70. The ELPIS II Phase 2b trial for HLHS failed its primary endpoint, and the company has initiated a strategic review process with Lucid Capital Markets, exploring a potential sale or merger. Cash stands at $7.2M, expected to fund operations into Q1 2027.
- Q3 2026 net loss of $6.1M, or $1.91 per share, on revenue of $0.1M
- EPS of -$1.91 missed consensus of -$1.70 (surprise -12.4%)
- Revenue declined 16% YoY to $0.1M, in line with consensus of $0.8M? (consensus $800K appears to be annualized or misaligned; actual quarterly revenue $115K)
- ELPIS II Phase 2b trial for HLHS failed primary endpoint (RVEF at Month 12)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access